Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (45)

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Development and validation of a model to predict complex Mohs micrographic surgery in clinical practice: REGESMOSH scale

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 8, pp. 1587-1594

  3. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

    Actas Dermo-Sifiliograficas

  4. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  5. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)

    Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345

  6. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting

    International Journal of Dermatology

  7. [Translated article] BIOBADATOP Spanish Atopic Dermatitis Registry: Description and Early Findings

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T479-T487

  8. [Translated article] Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 6, pp. T494-T501

2022

  1. Complications Associated with Mohs Micrographic Surgery: Data from the Nationwide Prospective Cohort REGESMOHS

    Dermatology, Vol. 238, Núm. 2, pp. 320-328

  2. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

  3. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting

    Dermatologic Therapy, Vol. 35, Núm. 8

  4. Incomplete Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery)

    Journal of the European Academy of Dermatology and Venereology

  5. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis

    JAMA Dermatology, Vol. 158, Núm. 5, pp. 561-572

  6. Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

    Expert Opinion on Biological Therapy

  7. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer –Basal Cell Carcinoma or Squamous Cell Carcinoma-Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 5, pp. 451-458

  8. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

    Dermatologic Therapy, Vol. 35, Núm. 12

  9. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  10. Ustekinumab to guselkumab transitions: A series of 54 patients emulating the navigate trial in real life

    Dermatologic Therapy, Vol. 35, Núm. 10